Pasar al contenido principal

NANOTRANSPORTADORES LIPIDICOS FUNCIONALIZADOS CON CANNABIDIOL PARA EL TRATAMIENTO DE TUMORES CEREBRALES

PID2019-105531RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

An overview of in vitro 3D models of the blood-brain barrier as a tool to predict the in vivo permeability of nanomedicines

  • Pérez-López, Alexandre
  • Torres Suárez, Ana Isabel
  • Martín Sabroso, Cristina
  • Aparicio Blanco, Juan
The blood–brain barrier (BBB) prevents efficient drug delivery to the central nervous system. As a result, brain diseases remain one of the greatest unmet medical needs. Understanding the tridimensional structure of the BBB helps gain insight into the pathology of the BBB and contributes to the development of novel therapies for brain diseases. Therefore, 3D models with an ever-growing sophisticated complexity are being developed to closely mimic the human neurovascular unit. Among these 3D models, hydrogel-, spheroid- and organoid-based static BBB models have been developed, and so have microfluidic-based BBB-on-a-chip models. The different 3D preclinical models of the BBB, both in health and disease, are here reviewed, from their development to their application for permeability testing of nanomedicines across the BBB, discussing the advantages and disadvantages of each model. The validation with data from in vivo preclinical data is also discussed in those cases where provided.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Improved drug delivery across the blood-brain barrier through post-insertion functionalization of lipid nanocapsules with cannabidiol using click chemistry

  • Pérez-López, Alexandre
  • Aparicio-Blanco, Juan
  • Martín-Sabroso, Cristina
  • Martins, Cláudia
  • Gómez-Lázaro, Laura
  • Sebastián, Víctor
  • González-Matilla, Juan Francisco
  • Sarmento, Bruno
  • Torres-Suárez, Ana I.
Crossing the blood-brain barrier (BBB) remains a major challenge in drug delivery for central nervous system (CNS) diseases. This study presents a covalent functionalization strategy to attach cannabidiol (CBD), the major non-psychotropic phytocannabinoid, to lipid nanocapsules (LNCs) to enhance their BBB permeability in vitro and in vivo. Using click chemistry, two highly monodisperse CBD-functionalized LNC formulations are prepared, LNC1CBD and LNC2CBD, with sizes of 27.0 ± 0.8 nm and 55.0 ± 2.5 nm, and functionalization efficiencies of 30.82 ± 5.93% and 29.59 ± 8.34%, respectively. LNC2CBD exhibits a 55.77% increase in cellular uptake relative to non-functionalized LNCs. In vitro permeability assays demonstrate that LNC1CBD significantly enhances translocation across the healthy BBB at earlier timepoints (4, 8 and 12 h), whereas LNC2CBD exhibits enhanced permeability at later stages (12 and 24 h) compared to their non-functionalized counterparts. This trend is maintained in a diseased BBB model, where CBD functionalization significantly improves permeability at nearly all timepoints for both formulations. Biodistribution studies in healthy mice validate these findings. LNC1CBD significantly increases brain accumulation by 14.87% at 30 min, while LNC2CBD maintains this effect, reaching 17.64% at 30 min, 38.23% at 90 min and 73.53% at 240 min, relative to non-functionalized LNCs. These findings underscore the potential of LNCs covalently functionalized with CBD as a promising platform for CNS-targeted delivery, which can ultimately open new avenues for therapeutic agents that do not usually reach the brain parenchyma at effective concentrations., This work was supported by the Spanish Ministry of Science, Innovation and Universities through the research project PID2019–105531RB-I00/AEI/10.13039/501100011033, titled “Lipid nanocarriers functionalized with cannabidiol for the treatment of brain tumours (NANOGLIO)”. Furthermore, A.P.L acknowledges the Community of Madrid for his contract (Ref. PIPF-2022/SAL-GL-25048) and the Complutense University of Madrid for funding a research stay at i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal under the Erasmus Plus program. L.G.L acknowledges the Complutense University of Madrid and Santander Bank for financial support (CT82/20-CT83/20). This work was supported by MOBILIsE Project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 951723. This work was also supported by FCT—Fundação para a Ciência e a Tecnologia in the framework of the project COMPETE2030-FEDER-00683900. C. M. acknowledges CEEC contract (2023.07049.CEECIND). V. S. acknowledges support from the Spanish Ministry of Science and Innovation (grant PID2021–127847OB-I00), as well as the CIBER-BBN, ELECMI and NANBIOSIS ICTSs., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Improved drug delivery across the blood-brain barrier through post-insertion functionalization of lipid nanocapsules with cannabidiol using click chemistry

  • Pérez-López, Alexandre
  • Aparicio-Blanco, Juan
  • Martín-Sabroso, Cristina
  • Martins, Cláudia
  • Gómez-Lázaro, Laura
  • Sebastián, Víctor
  • González-Matilla, Juan Francisco
  • Sarmento, Bruno
  • Torres-Suárez, Ana Isabel
Crossing the blood-brain barrier (BBB) remains a major challenge in drug delivery for central nervous system (CNS) diseases. This study presents a covalent functionalization strategy to attach cannabidiol (CBD), the major non-psychotropic phytocannabinoid, to lipid nanocapsules (LNCs) to enhance their BBB permeability in vitro and in vivo. Using click chemistry, two highly monodisperse CBD-functionalized LNC formulations are prepared, LNC1CBD and LNC2CBD, with sizes of 27.0 ± 0.8 nm and 55.0 ± 2.5 nm, and functionalization efficiencies of 30.82 ± 5.93% and 29.59 ± 8.34%, respectively. LNC2CBD exhibits a 55.77% increase in cellular uptake relative to non-functionalized LNCs. In vitro permeability assays demonstrate that LNC1CBD significantly enhances translocation across the healthy BBB at earlier timepoints (4, 8 and 12 h), whereas LNC2CBD exhibits enhanced permeability at later stages (12 and 24 h) compared to their non-functionalized counterparts. This trend is maintained in a diseased BBB model, where CBD functionalization significantly improves permeability at nearly all timepoints for both formulations. Biodistribution studies in healthy mice validate these findings. LNC1CBD significantly increases brain accumulation by 14.87% at 30 min, while LNC2CBD maintains this effect, reaching 17.64% at 30 min, 38.23% at 90 min and 73.53% at 240 min, relative to non-functionalized LNCs. These findings underscore the potential of LNCs covalently functionalized with CBD as a promising platform for CNS-targeted delivery, which can ultimately open new avenues for therapeutic agents that do not usually reach the brain parenchyma at effective concentrations.